Study Comparing Outcomes of Catheter-Based Treatments for Acute Pulmonary Embolism in Hong Kong

What this Trial Is About

Researchers are comparing different catheter-based treatments for patients with acute pulmonary embolism PE, a serious condition that can worsen quickly and cause death without timely care. The study focuses on two main types of catheter therapies catheter-directed thrombolysis, which uses medication to dissolve clots, and aspiration thrombectomy, which physically removes clots. The goal is to evaluate how these treatments differ in safety, effectiveness, and clinical outcomes using data from patients treated in Hong Kong hospitals. The treatments being compared include catheter-directed thrombolysis methods like ultrasound-assisted EKOS, and aspiration thrombectomy devices such as Penumbra, Flowtriever, and AlphaVac. This retrospective study collects past patient data from January 2016 to December 2021 to analyze outcomes after these procedures. Since this is a registry study, no new treatments are given instead, existing clinical records are reviewed to understand the impacts of these therapies. Participants medical records are examined to measure outcomes including mortality during hospital stay, complications within 72 hours post-procedure, changes in heart and lung function, bleeding events, and longer-term mortality up to 90 days. The study ensures privacy by removing identifying details and securely storing data. The total participation involves data collection and analysis without active patient involvement, covering treatment outcomes during hospital stay and follow-up periods.

Cohort Study on Treatment Comes of Catheter-based Therapy in Patients With Acute Pulmonary Embolism in Hong Kong